About US
Contact us
-
Shantha gets go-ahead for operational revampSanofi's ($SNY) plan for revamping Shantha Biotech won Indian government approval, clearing the way for it to recapture WHO contracts for its Shan5 vaccine. The health agency barred Shan5 in 2010 afte2012/5/15
-
Servier, founder face trial on Mediator chargesFrance's Mediator scandal has hit the courtroom. The drug's maker, Servier, and its founder are on trial in Nanterre, accused of misleading patients and regulators about the diabetes drug, often pr2012/5/15
-
India's drug regulator says it will clean up its actIndia's health agency has vowed that its top drug regulator will clean up its act, saying it will cinch up oversight rules for letting drugs on the market. Today's announcement comes a couple of days2012/5/14
-
FDA review questions long-term use of bone-building drugsThe FDA is giving women a lot to chew on with a new analysis of long-term use of drugs for osteoporosis because they can, although rarely, have a debilitating effect. The review was published Wedn2012/5/14
-
SFDA Chief of Discipline Inspection Group Yu Xiancheng visits the Netherlands Health Care Inspectorate and signs MOUOn April 19, 2012, Yu Xiancheng, Chief of Discipline Inspection Group of the State Food and Drug Administration (SFDA), signed the Memorandum of Understanding Between the State Food and Drug Administr2012/5/11
-
A strike against sales-rep OT as Lilly, Abbott win appealDon't count pharma out in the sales-rep overtime fight. As Pharmalot reports, a U.S. appeals court has denied overtime for Eli Lilly ($LLY) and Abbott Laboratories ($ABT) sales reps. The reps quali2012/5/11
-
Lipitor copy powers a surge in Ranbaxy sales, profitsWhat a difference generic Lipitor can make. Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat, to 12.47 billion rupees--$234.3 million--from 3.04 bil2012/5/10
-
FDA panel nixes Regeneron's Arcalyst for goutRegeneron ($REGN) may not be able to aim Aracalyst at the lucrative gout market. The would-be indication was shot down in an FDA advisory committee meeting, putting a new approval in doubt. Arcalyst i2012/5/10
-
Europe may be austere, but it's also hiring in pharmaPharma is hiring. Not in the U.S. so much, nor in hot spots like the Asia Pacific region. No, according to a report from corporate recruiters ZRG Partners, the biggest increase in pharma hiring for2012/5/9
-
Docs riled by FDA's proposal to open up drug accessThe FDA wants to knock down obstacles to certain drug treatments. It's an idea doctors abhor and insurers cautiously embrace, and one the FDA has floated before, if in other forms. If it reclassifi2012/5/9